Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer.
Nie, Keke
Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. [electronic resource] - Lung cancer (Amsterdam, Netherlands) 07 2018 - 5-11 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1872-8332
10.1016/j.lungcan.2018.04.012 doi
Acrylamides
Adult
Aniline Compounds
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bevacizumab--therapeutic use
Carcinoma, Non-Small-Cell Lung--drug therapy
Disease-Free Survival
Docetaxel--therapeutic use
ErbB Receptors--genetics
Female
Humans
Lung Neoplasms--drug therapy
Male
Middle Aged
Mutation--genetics
Piperazines--therapeutic use
Proportional Hazards Models
Osimertinib compared docetaxel-bevacizumab as third-line treatment in EGFR T790M mutated non-small-cell lung cancer. [electronic resource] - Lung cancer (Amsterdam, Netherlands) 07 2018 - 5-11 p. digital
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1872-8332
10.1016/j.lungcan.2018.04.012 doi
Acrylamides
Adult
Aniline Compounds
Antineoplastic Combined Chemotherapy Protocols--therapeutic use
Bevacizumab--therapeutic use
Carcinoma, Non-Small-Cell Lung--drug therapy
Disease-Free Survival
Docetaxel--therapeutic use
ErbB Receptors--genetics
Female
Humans
Lung Neoplasms--drug therapy
Male
Middle Aged
Mutation--genetics
Piperazines--therapeutic use
Proportional Hazards Models